Founder of 23andMe buys back company out of bankruptcy auction

Anne Wojcicki's TTAM Research Institute won the bankruptcy auction for 23andMe with a $305 million bid, surpassing Regeneron Pharmaceuticals' previous $256 million offer. Regeneron declined to counter TTAM's final bid after a dispute over financing concerns in the initial auction, and will receive a $10 million termination fee. The deal allows Wojcicki to retain control of the genetics testing company free of existing liabilities after it rejected her previous go-private offers and subsequently filed for bankruptcy in March.

Analysis

TTAM Research Institute, a non-profit public benefit company founded by Anne Wojcicki, has successfully acquired the assets of genetics testing firm 23andMe for $305 million in a bankruptcy auction, notably without incurring any of 23andMe's existing liabilities. This acquisition follows 23andMe's Chapter 11 filing in March, which itself occurred after the company had rebuffed several go-private offers from Wojcicki, indicating her persistent interest in the venture. The auction process saw TTAM outbid Regeneron Pharmaceuticals, whose initial $256 million offer had been accepted in May before TTAM challenged the process, alleging it was prematurely concluded. TTAM's path to victory involved overcoming initial skepticism regarding its financing capabilities, which were subsequently validated by securing backing from a significant Fortune 500 company possessing over $400 billion in market capitalization and $17 billion in cash reserves. Regeneron opted not to submit a higher counter-offer to TTAM's final bid and is slated to receive a $10 million termination fee, partially compensating for its involvement. This outcome represents a strategic recapture of 23andMe's core operations by its founder under a new, unencumbered, non-profit structure, and underscores the dynamic nature of M&A and restructuring within the biotechnology sector, particularly for distressed entities with valuable underlying assets.

Key Decisions for Investors

• Existing equity holders in 23andMe (ME) should anticipate a near-complete loss of their investment, as the bankruptcy asset sale prioritizes creditors, a situation reflected in the highly negative sentiment (-0.9) associated with the ticker.
• For Regeneron (REGN) investors, the unsuccessful bid for 23andMe's assets, while resulting in a $10 million termination fee, is not expected to materially alter the company's financial outlook or strategic direction, aligning with its neutral sentiment signal.
• The acquisition by TTAM, supported by substantial financial backing, allows Anne Wojcicki to relaunch 23andMe's core genetic testing services under a new, debt-free non-profit structure, potentially shifting its operational focus towards research or public benefit rather than purely commercial objectives.
• Investors monitoring the healthcare and biotech sectors should view this transaction as indicative of ongoing value realization opportunities in distressed assets, particularly where strong intellectual property or founder commitment can drive restructuring efforts and lead to new organizational forms.